JP2025114555A5 - - Google Patents

Info

Publication number
JP2025114555A5
JP2025114555A5 JP2025062046A JP2025062046A JP2025114555A5 JP 2025114555 A5 JP2025114555 A5 JP 2025114555A5 JP 2025062046 A JP2025062046 A JP 2025062046A JP 2025062046 A JP2025062046 A JP 2025062046A JP 2025114555 A5 JP2025114555 A5 JP 2025114555A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
formula
sbebcd
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025062046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025114555A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/032941 external-priority patent/WO2020232274A1/en
Application filed filed Critical
Publication of JP2025114555A publication Critical patent/JP2025114555A/ja
Publication of JP2025114555A5 publication Critical patent/JP2025114555A5/ja
Pending legal-status Critical Current

Links

JP2025062046A 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤 Pending JP2025114555A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962848420P 2019-05-15 2019-05-15
US62/848,420 2019-05-15
PCT/US2020/032941 WO2020232274A1 (en) 2019-05-15 2020-05-14 Ketamine formulation for subcutaneous injection
JP2021568611A JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021568611A Division JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Publications (2)

Publication Number Publication Date
JP2025114555A JP2025114555A (ja) 2025-08-05
JP2025114555A5 true JP2025114555A5 (https=) 2025-10-28

Family

ID=73230954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Country Status (6)

Country Link
US (2) US10973780B2 (https=)
EP (1) EP3968979A4 (https=)
JP (2) JP2022533971A (https=)
CN (2) CN121489917A (https=)
CA (1) CA3140046A1 (https=)
WO (1) WO2020232274A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
CN121489917A (zh) * 2019-05-15 2026-02-10 贝克森生物医药公司 用于皮下注射的氯胺酮制剂
JP7814375B2 (ja) 2020-08-18 2026-02-16 オークウッド ラボラトリーズ，エル．エル．シー． ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
WO2022109050A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤
CA3245931A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. R-KETAMINE PHARMACEUTICAL FORMULATIONS
US20250345458A1 (en) * 2022-05-18 2025-11-13 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
IN202221054235A (https=) 2022-09-22 2023-11-03
CN120936348A (zh) * 2023-02-15 2025-11-11 克力迈实验室公司 任选地与n-酰基乙醇胺组合地包含氯胺酮的组合物及其用途
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU2004308935A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
CN101765582A (zh) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
EP3904332B1 (en) * 2011-10-14 2024-12-04 The United States of America, as represented by The Secretary, Department of Health and Human Services The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
EP2830604A4 (en) * 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
US20130296437A1 (en) 2012-05-04 2013-11-07 E-Therapeutics Plc Treatment of Depression
US10124940B2 (en) 2012-09-11 2018-11-13 Zolo Solutions, Inc. Systems, methods, and devices for dispensing one or more substances
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
CN121489917A (zh) * 2019-05-15 2026-02-10 贝克森生物医药公司 用于皮下注射的氯胺酮制剂

Similar Documents

Publication Publication Date Title
JP2025114555A5 (https=)
KR810000900B1 (ko) 항생물질 조성제의 안정화 방법
JP2025016462A (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JPS6146455B2 (https=)
JP7738696B2 (ja) フロセミドの濃縮液体医薬製剤及びそれを投与する方法
JPWO2020232274A5 (https=)
CN114630669B (zh) 稳定的医药组合物
US20050004221A1 (en) Intrathecal gabapentin compositions
US5118698A (en) Pharmaceutical preparations
JP7090845B2 (ja) パロノセトロン含有液体組成物
EP1682149B1 (en) Injectable gabapentin compositions
US2919228A (en) Parenteral composition to reduce duration of local anesthesia
HK40074840A (en) Stable pharmaceutical composition
TW202523320A (zh) 用於皮下投與之包含普拉曲沙之組合物及其使用方法
HK40074840B (zh) 稳定的医药组合物
RU2578433C1 (ru) Противотуберкулёзная фармацевтическая композиция для парентерального применения в дозировках малого объема
JPWO2021189051A5 (https=)
CN101073552A (zh) 盐酸椎双净鼻用凝胶喷雾剂及其应用
US20040019075A1 (en) New formulation for the parenteral application of crobenetine
RU2024116274A (ru) Кристаллическая форма гемитартратной соли (r)-2-(трет-бутиламино)-1-(5-фторпиридин-3-ил)-этан-1-ола для лечения гипергликемии и диабета 2-го типа
JPWO2022132655A5 (https=)
JPWO2022263792A5 (https=)
JP2005531573A (ja) クロベネチンの非経口的用途用の新規製剤
JPWO2023151513A5 (https=)
JP2000119177A (ja) 鎮痛剤